Axonics acquired assets of Radian, terms not disclosed

Axonics announced the acquisition of a lead placement solution from Radian that complements Axonics’ existing sacral neuromodulation offering. The technology has the potential to reduce procedure time and facilitate a more accurate placement which, in turn, can increase physicians’ confidence in the SNM procedure and drive increased therapy adoption, utilization and permanent implant conversion rates. Axonics has acquired the assets of Radian from Intermed Labs for undisclosed terms. Axonics expects the product to receive FDA clearance and be available on a commercial basis in mid-2024.